42 results about "Sarpogrelate Hydrochloride" patented technology

Provided is a preparing method of sarpogrelate hydrochloride, characterized in that 2-((3-methoxyl)styrylcoumarin)phenol mixture containing triphenylphosphine oxide is catalyzed and hydrogenated, and then reacted with epichlorohydrin and dimethylamine to obtain 2-(dimethylamino)-1-(o-(m-methoxyphenylethyl)phenoxymethyl)ethanol, at the same time, triphenylphosphine oxide is separated or not, reacted with succinic anhydride, salt-formed with chlorine hydride, and re-crystallization by a proper solvent, so as to obtain sarpogrelate hydrochloride.

The invention relates to the medicine technical filed, in particular to a monolayer osmotic pump controlled release preparation of sarpogrelate hydrochloride and a preparation method thereof, which is characterized by lasting drug effect, constant curative effect, slight toxic and side effect. The monolayer osmotic pump controlled release preparation of sarpogrelate hydrochloride comprises by weight percentage of 1 to 40 percent of sarpogrelate hydrochloride, 30 to 90 percent of auxiliary material that can promote osmosis, 1 to 40 percent of membrane material that performs controlled release and the rest is other auxiliary material; the diameter of a small drug release hole is 0.1 to 2.0 mm. The preparation method comprises: a certain amount of drug according to the prescription is mixed with an adhesive, a bulking agent and a co-penetrant which are respectively ground and screened, prepared into soft material and palletized, dried and particle finished and then added with a lube and pressed to obtain tablet core. Coating liquid is prepared and the tablet core coated, after coating, drying is done to solidify the coating membrane, and then one side of coated tablet is provided with the small drug release hole, thus obtaining an osmotic pump controlled release tablet. The monolayer osmotic pump controlled release preparation of sarpogrelate hydrochloride of the invention has the advantages of reducing times of dosage, promoting the compliance of sufferers and satisfying the requirements of clinical medication.

Provided is an orally administrable preparation of hydrochloride sarpogrelate facilitating the administration by miniaturization. The miniaturized orally administrable preparation of the hydrochloride sarpogrelate has a high content of >=40% of the hydrochloride sarpogrelate per preparation, and exhibits good manufacturability by suppressing tablet trouble. The preparation also has a rapid elution rate from the preparation in the alimentary tract, and exhibits good preservation stability.

A drug releasing medical device of the invention is provided with a controlled drug release composition containing 100 parts by weight of an organic polymeric material which is soluble in an organic solvent and insoluble in water, 5 to 60 parts by weight of a release auxiliary agent which is lipid-soluble and low in molecular weight and a 1 to 70 parts by weight of a drug. When the composition is applied to a stent, a catheter, an organ replacement medical device, an artificial organ or the like in the form of coating or the like, a drug releasing function is given to the medical device. From a surface of a stent for treating coronary stenosis, which is a preferred embodiment, argatroban, sarpogrelate hydrochloride or both of them are released gradually. In order to express a controlled release property in a desired period of time, the drug to be released gradually is carried in a polymeric material coated on a metal surface constituting the stent or in a porous stent substrate. It is preferred that the polymeric material is noncrystalline and further biodegradable and contains a tartaric acid ester, a malic acid ester or a monoester or diester of glycerine as the release auxiliary agent.

The invention relates to a sarpogrelate hydrochloride sustained release preparation and a preparation method thereof. The sarpogrelate hydrochloride sustained release preparation provided by the invention is invented for slowing down the release speed of a sarpogrelate hydrochloride medicine. The main components of the preparation provided by the invention can release medicines continuously in the gastrointestinal tract for over 24 hours.

The invention belongs to the field of pharmaceutical synthesis and specifically relates to a preparation method of sarpogrelate hydrochloride photodegradation impurities. According to the preparation method, salicylaldehyde is used as a raw material to prepare a degradation impurity II by three steps of a substitution reaction, an addition reaction and an esterification reaction, etc., and a crude product undergoes column chromatography isolation such that purity reaches more than 99%; 2-[2-(3-methoxyphenyl)ethylene]phenol is used as a raw material to prepare a sarpogrelate hydrochloride impurity III by five steps of a substitution reaction, an addition reaction, an esterification reaction, an epoxidation reaction and a reduction reaction, etc., and a crude product undergoes column chromatography isolation such that purity reaches more than 99%; and [[2-[2-(3-methoxyphenyl)ethyl]phenoxyl]methyl]oxirane is used as a raw material to prepare a sarpogrelate hydrochloride gradation impurity IV by four steps of an addition reaction, amino protection, an esterification reaction and deprotection, etc., and a crude product undergoes column chromatography isolation such that purity reaches more than 99%. The preparation method is simple to operate, and reactions are mild. Product purity is high. The preparation method is suitable for impurity spectrum analysis. By the preparation method, overall yield is high.

The invention provides a sarpogrelate intermediate and a preparation method thereof. The sarpogrelate intermediate is a compound shown as formula VI. The preparation method of the intermediate comprises a Grignard reaction of salicylic aldehyde with phenolic groups protected and a Grignard reagent. The method is mild in reaction conditions, low in energy consumption and small in pollutions, and has relatively high conversion rate and low cost of the raw materials. The obtained sarpogrelate hydrochloride has high purity with the detection purity of HPLC higher than 99%. The method is suitable for large-scale production conversion.

The invention provides a low-release sarpogrelate hydrochloride medicament. The main ingredients of the medicament can be continuously released in the gastrointestinal tract for over 10h.

The invention discloses a preparation method for sarpogrelate hydrochloride. The method comprises the steps of preparation of the intermediate [[2-(3-methoxyphenyl)ethyl]phenoxyl]methyl]oxirane, 1-dimethylamino-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxyl]2-propyl alcohol and a finished product in order. According to the invention, ethanol with a concentration of 95% is used as a solvent, and substituted sodium hydride is changed into sodium hydroxide or potassium hydroxide or the like; therefore, cost is reduced, operation is simple, and the finished product has stable quality.

The invention provides a preparation method of sarpogrelate hydrochloride. The sarpogrelate hydrochloride is shown as Formula I. The method comprises the following steps of 1) performing the following dehydration reaction on sarpogrelate intermediate shown as formula VI in the presence of an acid dehydrating agent to obtain a compound shown as formula VII; and 2) further preparing the sarpogrelate hydrochloride from the compound shown as the formula VII. The method is mild in reaction conditions, low in energy consumption and small in pollution, and has relatively high conversion rate and low raw material cost. The obtained sarpogrelate hydrochloride has high purity with detection purity of HPLC over 99%, and is suitable for large-scale production conversion.

The invention discloses a method for detecting dimethylamine and dimethylamine hydrochloride in a sarpogrelate hydrochloride intermediate C. The method is simple, and favorable in precision, accuracy,reproducibility and durability. The method can be used for detecting the dimethylamine and the dimethylamine hydrochloride in the sarpogrelate hydrochloride intermediate C, i.e. 1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl) ethyl] phenoxy]-2-propanol hydrochloride.

The invention discloses a synthetic method of a sarpogrelate intermediate 2-[2-(3-methoxyphenyl)ethyl]phenol and relates to the technical field of organic synthesis. In the method, with m-methoxyl chlorobenzene, which is easy to obtain and is low in cost, as a raw material, the method includes the steps of: 1) performing condensation to the raw material with triethyl phosphite; and 2) performing condensation with o-phenylmethoxyl benzaldehyde (which is prepared from salicylic acid and chlorobenzene), performing hydrogenation to alkylate a double bond, and crystallizing a product with petroleum ether to prepare a white crystal target product. The method simplifies process steps, reduces loss ratio and is 99.5% in product purity. The 2-[2-(3-methoxyphenyl)ethyl]phenol is used for preparing sarpogrelate hydrochloride, wherein single impurity is less than 0.1% in content and the product purity reaches more than 99.8%.

The invention provides a sarpogrelate hydrochloride tablet. The sarpogrelate hydrochloride tablet is composed of the following raw and accessory materials by weight: 100 parts of sarpogrelate hydrochloride, 60 to 100 parts of microcrystalline cellulose PH302, 4 to 8 parts of citric acid, 2 to 6 parts of magnesium stearate, 8 to 12 parts of aerosil and 5 to 6 parts of Opadry (registeration trademark) 295F6800. The tablet has low preparation cost and better stability compared with commercially available preparations. The invention also provides a preparation method for the sarpogrelate hydrochloride tablet to overcome contradiction between minimal accessory materials and particle mobility. Research results in the invention prove that when sarpogrelate hydrochloride and citric acid are mixed and crushed to specific particle sizes in advance and then mixed with microcrystalline cellulose of a specific model, the requirement on mobility of mixed particles during direct pressing of powder is met and the dissolving-out behavior of the tablet is realized; and results of stability test show that the tablet has better stability compared with commercially available preparations.

The invention discloses a method for detecting related substances of sarpogrelate hydrochloride intermediate C. The method is simple, and the precision, accuracy, reproducibility and durability are good. The method can be used for quality control of the related substances of the sarpogrelate hydrochloride raw material intermediate C, namely 1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]-2-propyl-alcohol hydrochloride.

The invention aims to disclose sarpogrelate hydrochloride prepared by a convenient and environment-friendly method, relates to a solvent, in particular to a solvent which is prepared by free condensation of 2-[2-(3-methoxyphenyl) ethyl] phenol and epoxy chloropropane (2-[2-(3-metoxypherol) ethyl] pherol withepoxychloropropane). Under atmospheric pressure, dimethylamine is used for ring opening ofethylene oxide of the obtained intermediate, and then the intermediate reacts with succinic anhydride to obtain sarpogrelate. The obtained free alkali is treated by using isopropanol IPA.HCl to obtainthe sarpogrelate hydrochloride. Crystals of hydrochloride are formed in acetone, and a pure product is obtained. According to the preparation method, solvent-free reaction is adopted in the first step, atmospheric pressure reaction is adopted in the second step, and thus the preparation method is suitable for industrial production.

The invention discloses a method for removing residuals of sarpogrelate hydrochloride in a high-performance liquid chromatography sample injection valve. The sample injection valve is cleaned through multiple times of sample injection of a blank solvent, wherein the blank solvent is a N-methyl pyrrolidone aqueous solution with the volume percent fraction of 50%-70%. Sarpogrelate hydrochloride is a 5-HT2 receptor blocker, can inhibit platelet aggregation and vasoconstriction and has an anti-thrombotic effect and a microcirculation improving effect. The compound is very liable to remain in the sample injection valve although the water solubility is very good, then a small peak can occur at the sarpogrelate peak appearance position even though the blank solvent is injected, a quantitation limit and detection limit determination experiment of sarpogrelate hydrochloride can not be carried out at all due to the phenomenon, and the sarpogrelate hydrochloride content determination accuracy is influenced. According to the method, the efficiency of removing the sarpogrelate hydrochloride residues in the sample injection valve is high, and the working efficiency can be improved.

The invention discloses a method for synthesizing 2-(3-dimethylamino-2-hydroxy) propoxybenzaldehyde as an intermediate of sarpogrelate hydrochloride, and relates to the technical field of pharmaceutical organic synthesis.Salicylaldehyde is used as a raw material, the salicylaldehyde and epichlorohydrin are subjected to etherification reaction in the presence of a deacid reagent to generate theintermediate 2-(ethylene oxide-2-methoxy) benzaldehyde,and then the intermediate 2-(ethylene oxide-2-methoxy) benzaldehydeis aminated with dimethylamine to generate 2-(3-dimethylamino-2-hydroxy) propoxybenzaldehyde.According to the method for synthesizing the 2-(3-dimethylamino-2-hydroxy) propoxybenzaldehyde as the intermediate of the sarpogrelate hydrochloride,2-(3-dimethylamino-2-hydroxy) propoxybenzaldehyde is prepared by two steps with the salicylaldehyde, no additional reaction solvent is added, the input cost of the reaction solvent is reduced, and the pollution to the environment caused bythe direct discharge of the reaction solvent or the increased energy consumption input of the recovery of the reaction solvent is avoided.

The invention discloses the use of sargrelate hydrochloride impurity I for inducing differentiation of bone marrow mesenchymal stem cells. The present invention provides the application of sarcogrelate hydrochloride impurity I in the preparation of drugs for inducing osteogenic differentiation of bone marrow mesenchymal stem cells. The cognition level of prior art to sarcogrelate hydrochloride impurity I; In order to overcome the problem of poor water solubility and low bioavailability of sarcogrelate hydrochloride impurity I-povidone K ‑30 solid dispersion, the preparation can significantly improve the water solubility of impurity Ⅰ of sarcogrelate hydrochloride, thereby improving its bioavailability.